Cancer patients get extended access to Life-Extending drug

NCT ID NCT05161195

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study allows patients with metastatic breast cancer who are already benefiting from ribociclib treatment in previous Novartis trials to continue receiving the medication. The main goal is to monitor long-term safety while providing continued access to the drug. Participants must have shown clinical benefit from at least 6 cycles of treatment in the original study.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beverly Hills Cancer Center

Beverly Hills, California, 90211, United States
Duly Health and Care

Plainfield, Illinois, 60585, United States
Eastchester Center for Cancer Care

The Bronx, New York, 10469, United States
Englewood Health

Englewood, New Jersey, 07631, United States
Highlands Oncology Group

Fayetteville, Arkansas, 72703, United States
Indian Univ Health Goshen Center forCancer

Goshen, Indiana, 46526, United States
Ironwood Cancer and Research Centers

Chandler, Arizona, 85224, United States
John D Archbold Memorial Hospital

Thomasville, Georgia, 31792, United States
Mid Florida Hematology And Onc Ctr

Orange, Florida, 32763, United States
Millennium Research Clin Develop

Houston, Texas, 77090, United States
Northern Light Mercy Hospital

Portland, Maine, 04102, United States
Novartis Investigative Site

San Juan, J5402DIL, Argentina
Novartis Investigative Site

Natal, Rio Grande do Norte, 59075 740, Brazil
Novartis Investigative Site

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Novartis Investigative Site

Florianópolis, Santa Catarina, 88020-210, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 01317 000, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 03102, Brazil
Novartis Investigative Site

Sao Jose Rio Preto, 15090 000, Brazil
Novartis Investigative Site

São Paulo, 01255-000, Brazil
Novartis Investigative Site

Chongqing, Chongqing Municipality, 404100, China
Novartis Investigative Site

Shijiazhuang, Hebei, 050011, China
Novartis Investigative Site

Harbin, Heilongjiang, 150081, China
Novartis Investigative Site

Changsha, Hunan, 410013, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Kunming, Yunnan, 650106, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310016, China
Novartis Investigative Site

Beijing, 100036, China
Novartis Investigative Site

Qingdao, 266000, China
Novartis Investigative Site

Shanghai, 200025, China
Novartis Investigative Site

Shanghai, 200032, China
Novartis Investigative Site

Tianjin, 300480, China
Novartis Investigative Site

San José, 95008, Costa Rica
Novartis Investigative Site

Heraklion Crete., 715 00, Greece
Novartis Investigative Site

Hong Kong, 999077, Hong Kong
Novartis Investigative Site

Bhubaneshwar, Odisha, 751007, India
Novartis Investigative Site

Delhi, 110085, India
Novartis Investigative Site

Meldola, FC, 47014, Italy
Novartis Investigative Site

Osaka, Osaka, 5400006, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138431, Japan
Novartis Investigative Site

Bunkyo Ku, Tokyo, 1138677, Japan
Novartis Investigative Site

Koto Ku, Tokyo, 1358550, Japan
Novartis Investigative Site

El Chouf, LBN, 1503201002, Lebanon
Novartis Investigative Site

Beirut, 113-0236, Lebanon
Novartis Investigative Site

Beirut, 166830, Lebanon
Novartis Investigative Site

San Pedro G G, 66278, Mexico
Novartis Investigative Site

Trujillo, La Libertad, 13011, Peru
Novartis Investigative Site

San Borja, Lima region, 41, Peru
Novartis Investigative Site

Gdansk, 80-214, Poland
Novartis Investigative Site

Lisbon, 1400-038, Portugal
Novartis Investigative Site

Loures, 2674-514, Portugal
Novartis Investigative Site

Porto, 4200-072, Portugal
Novartis Investigative Site

Singapore, 119228, Singapore
Novartis Investigative Site

Cape Town, 7500, South Africa
Novartis Investigative Site

Johannesburg, 2196, South Africa
Novartis Investigative Site

Pretoria, 0002, South Africa
Novartis Investigative Site

Seoul, Korea, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Sant Joan Despí, Barcelona, 08970, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Malatya, Battalgazi, 44280, Turkey (Türkiye)
Novartis Investigative Site

Diyarbakır, Sur, 21280, Turkey (Türkiye)
Novartis Investigative Site

Izmir, 35100, Turkey (Türkiye)
Novartis Investigative Site

Kecioren Ankara, 06010, Turkey (Türkiye)
Novartis Investigative Site

Hanoi, 100000, Vietnam
Oklahoma Cancer Specialists and Research Institute

Tulsa, Oklahoma, 74136, United States
Poudre Valley Hospital

Fort Collins, Colorado, 80528, United States
Summit Cancer Care

Savannah, Georgia, 31405, United States
The Valley Hospital-Luckow Pavillion

Paramus, New Jersey, 07652, United States
University Hospitals of Cleveland Seidman Cancer Center

Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC BREAST CANCER